We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Tolfenamic acid is a potent CYP1A2 inhibitor in vitro but does not interact in vivo: correction for protein binding is needed for data interpretation.
- Authors
Karjalainen, Marjo J.; Neuvonen, Pertti J.; Backman, Janne T.
- Abstract
Our aim was to correlate the in vitro and in vivo CYP1A2 inhibition potential of tolfenamic acid, an NSAID highly (99.7%) bound to plasma proteins, to study the significance of protein binding of inhibitor in metabolic drug interactions. The effect of tolfenamic acid on CYP1A2 (phenacetin O-deethylation) was studied using human liver microsomes, with and without albumin (0–10 mg/ml). In a randomized, crossover study, 10 volunteers took 200 mg tolfenamic acid or placebo t.i.d. for 3 days. On day 2, a caffeine test was performed. On day 3, each ingested 4 mg of the CYP1A2 substrate tizanidine. Plasma tizanidine, its metabolites (M) and tolfenamic acid, and pharmacodynamic variables were measured. Tolfenamic acid strongly inhibited phenacetin-O-deethylation in vitro (IC50 1.8 μM without albumin). Albumin decreased its inhibitory effect in a concentration-dependent manner; the IC50 exceeded 100 μM with 10 mg/ml of albumin. Tolfenamic acid had no effect on the area under the concentration-time curve $${\left( {{\text{AUC}}_{{0 - \infty }} } \right)}$$ , peak concentration, time of peak concentration or half-life of tizanidine or M-3; only the $${\text{AUC}}_{{0 - \infty }} $$ of secondary metabolite M-4 was slightly decreased (13%, P = 0.004). The caffeine test and the pharmacodynamic effects of tizanidine were unchanged. Tolfenamic acid potently inhibits CYP1A2 in vitro when studied without albumin, but not in vivo. This apparent discrepancy is due to the high protein binding of tolfenamic acid. To avoid overestimation of the interaction potential, the inhibitory effect of highly albumin-bound compounds should also be studied in vitro with albumin, or their exact unbound plasma concentration should be used in predictions.
- Subjects
PROTEIN binding; BLOOD proteins; ALBUMINS; ANTI-infective agents; PHARMACOKINETICS; PHENACETIN; ACETONITRILE
- Publication
European Journal of Clinical Pharmacology, 2007, Vol 63, Issue 9, p829
- ISSN
0031-6970
- Publication type
Article
- DOI
10.1007/s00228-007-0335-z